Your browser doesn't support javascript.
loading
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group: Report 3: Baseline Retinopathy and Clinical Features Predict Progression of Diabetic Retinopathy.
Lee, Cecilia S; Lee, Aaron Y; Baughman, Douglas; Sim, Dawn; Akelere, Toks; Brand, Christopher; Crabb, David P; Denniston, Alastair K; Downey, Louise; Fitt, Alan; Khan, Rehna; Mahmood, Sajad; Mandal, Kaveri; Mckibbin, Martin; Menon, Geeta; Lobo, Aires; Kumar, B Vineeth; Natha, Salim; Varma, Atul; Wilkinson, Elizabeth; Mitry, Danny; Bailey, Clare; Chakravarthy, Usha; Tufail, Adnan; Egan, Catherine.
Afiliação
  • Lee CS; Department of Ophthalmology, University of Washington, Seattle, Washington.
  • Lee AY; Department of Ophthalmology, University of Washington, Seattle, Washington; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom. Electronic address: leeay@uw.edu.
  • Baughman D; Department of Ophthalmology, University of Washington, Seattle, Washington.
  • Sim D; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
  • Akelere T; Hinchingbrooke Health Care NHS Trust, Huntingdon, United Kingdom.
  • Brand C; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
  • Crabb DP; City, University of London, Division of Optometry & Visual Science, London, United Kingdom.
  • Denniston AK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • Downey L; Hull Royal Infirmary, Department of Ophthalmology, Hull, United Kingdom.
  • Fitt A; Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, United Kingdom.
  • Khan R; Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom.
  • Mahmood S; Manchester Royal Eye Hospital, Manchester, United Kingdom.
  • Mandal K; Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom.
  • Mckibbin M; Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom.
  • Menon G; Frimley Park Hospital, Frimley, United Kingdom.
  • Lobo A; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
  • Kumar BV; Royal Hallamshire Hospital, Sheffield, United Kingdom.
  • Natha S; Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom.
  • Varma A; Mid Yorkshire Hospitals NHS Trust, Yorkshire, United Kingdom.
  • Wilkinson E; Northern Devon Healthcare NHS Trust, Devon, United Kingdom.
  • Mitry D; The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.
  • Bailey C; Bristol Eye Hospital, Bristol, United Kingdom.
  • Chakravarthy U; Belfast Health and Social Care Trust, Belfast, United Kingdom.
  • Tufail A; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.
  • Egan C; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom; The NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.
Am J Ophthalmol ; 180: 64-71, 2017 Aug.
Article em En | MEDLINE | ID: mdl-28572062
ABSTRACT

PURPOSE:

To determine the time and risk factors for developing proliferative diabetic retinopathy (PDR) and vitreous hemorrhage (VH).

DESIGN:

Multicenter, national cohort study.

METHODS:

Anonymized data of 50 254 patient eyes with diabetes mellitus at 19 UK hospital eye services were extracted at the initial and follow-up visits between 2007 and 2014. Time to progression of PDR and VH were calculated with Cox regression after stratifying by baseline diabetic retinopathy (DR) severity and adjusting for age, sex, race, and starting visual acuity.

RESULTS:

Progression to PDR in 5 years differed by baseline DR no DR (2.2%), mild (13.0%), moderate (27.2%), severe nonproliferative diabetic retinopathy (NPDR) (45.5%). Similarly, 5-year progression to VH varied by baseline DR no DR (1.1%), mild (2.9%), moderate (7.3%), severe NPDR (9.8%). Compared with no DR, the patient eyes that presented with mild, moderate, and severe NPDR were 6.71, 14.80, and 28.19 times more likely to develop PDR, respectively. In comparison to no DR, the eyes with mild, moderate, and severe NPDR were 2.56, 5.60, and 7.29 times more likely to develop VH, respectively. In severe NPDR, the eyes with intraretinal microvascular abnormalities (IRMA) had a significantly increased hazard ratio (HR) of developing PDR (HR 1.77, 95% confidence interval [CI] 1.25-2.49, P = .0013) compared with those with venous beading, whereas those with 4-quadrant dot-blot hemorrhages (4Q DBH) had 3.84 higher HR of developing VH (95% CI 1.39-10.62, P = .0095).

CONCLUSIONS:

Baseline severities and features of initial DR are prognostic for PDR development. IRMA increases risk of PDR whereas 4Q DBH increases risk of VH.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemorragia Vítrea / Neovascularização Retiniana / Retinopatia Diabética Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Am J Ophthalmol Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemorragia Vítrea / Neovascularização Retiniana / Retinopatia Diabética Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Am J Ophthalmol Ano de publicação: 2017 Tipo de documento: Article